{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:21:37Z","timestamp":1791397297583,"version":"4.3.3"},"reference-count":108,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,12,29]],"date-time":"2019-12-29T00:00:00Z","timestamp":1577577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009543","name":"Pontificia Universidad Javeriana","doi-asserted-by":"publisher","award":["PPTA 7520"],"award-info":[{"award-number":["PPTA 7520"]}],"id":[{"id":"10.13039\/501100009543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007637","name":"Departamento Administrativo de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n (COLCIENCIAS)","doi-asserted-by":"publisher","award":["Grant ID 120380763212 \u2013 PPTA 8352"],"award-info":[{"award-number":["Grant ID 120380763212 \u2013 PPTA 8352"]}],"id":[{"id":"10.13039\/100007637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The mucopolysaccharidoses (MPS) are a group of 11 lysosomal storage diseases (LSDs) produced by mutations in the enzymes involved in the lysosomal catabolism of glycosaminoglycans. Most of the mutations affecting these enzymes may lead to changes in processing, folding, glycosylation, pH stability, protein aggregation, and defective transport to the lysosomes. It this sense, it has been proposed that the use of small molecules, called pharmacological chaperones (PCs), can restore the folding, trafficking, and biological activity of mutated enzymes. PCs have the advantages of wide tissue distribution, potential oral administration, lower production cost, and fewer issues of immunogenicity than enzyme replacement therapy. In this paper, we will review the advances in the identification and characterization of PCs for the MPS. These molecules have been described for MPS II, IVA, and IVB, showing a mutation-dependent enhancement of the mutated enzymes. Although the results show the potential of this strategy, further studies should focus in the development of disease-specific cellular models that allow a proper screening and evaluation of PCs. In addition, in vivo evaluation, both pre-clinical and clinical, should be performed, before they can become a real therapeutic strategy for the treatment of MPS patients.<\/jats:p>","DOI":"10.3390\/ijms21010232","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T05:49:41Z","timestamp":1577684981000},"page":"232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses"],"prefix":"10.3390","volume":"21","author":[{"given":"Juan Camilo","family":"Losada D\u00edaz","sequence":"first","affiliation":[{"name":"Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogot\u00e1 D.C. 110231, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Cepeda del Castillo","sequence":"additional","affiliation":[{"name":"Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogot\u00e1 D.C. 110231, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5409-3466","authenticated-orcid":false,"given":"Edwin Alexander","family":"Rodriguez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogot\u00e1 D.C. 110231, Colombia"},{"name":"Chemistry Department, Faculty of Science, Pontificia Universidad Javeriana, Bogot\u00e1 D.C. 110231, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-1173","authenticated-orcid":false,"given":"Carlos J.","family":"Alm\u00e9ciga-D\u00edaz","sequence":"additional","affiliation":[{"name":"Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogot\u00e1 D.C. 110231, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1152\/physrev.00001.2011","article-title":"The unfolded protein response: Integrating stress signals through the stress sensor IRE1alpha","volume":"91","author":"Hetz","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1152\/physrev.00029.2016","article-title":"Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases","volume":"98","author":"Tao","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nature17041","article-title":"Protein misfolding in the endoplasmic reticulum as a conduit to human disease","volume":"529","author":"Wang","year":"2016","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.molcel.2004.08.025","article-title":"Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death","volume":"15","author":"Haynes","year":"2004","journal-title":"Mol. Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"40282","DOI":"10.1074\/jbc.M508786200","article-title":"HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin","volume":"280","author":"Iwata","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1126\/science.1067389","article-title":"Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson\u2019s disease","volume":"295","author":"Auluck","year":"2002","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6229","DOI":"10.1073\/pnas.92.14.6229","article-title":"Cotranslational folding and calnexin binding during glycoprotein synthesis","volume":"92","author":"Chen","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrm3658","article-title":"Chaperone machines for protein folding, unfolding and disaggregation","volume":"14","author":"Saibil","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1139\/O09-175","article-title":"Mechanisms of the Hsp70 chaperone system","volume":"88","author":"Young","year":"2010","journal-title":"Biochem. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/nsmb.2908","article-title":"Structural basis for interaction of a cotranslational chaperone with the eukaryotic ribosome","volume":"21","author":"Zhang","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.celrep.2015.03.063","article-title":"Hsp70 forms antiparallel dimers stabilized by post-translational modifications to position clients for transfer to Hsp90","volume":"11","author":"Morgner","year":"2015","journal-title":"Cell Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.bbapap.2006.08.012","article-title":"Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs","volume":"1764","author":"Arakawa","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/nature02265","article-title":"Therapeutic approaches to protein-misfolding diseases","volume":"426","author":"Cohen","year":"2003","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mce.2007.04.012","article-title":"Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro","volume":"272","author":"Janovick","year":"2007","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1087057109357789","article-title":"Ligand detection in the allosteric world","volume":"15","author":"Kenakin","year":"2010","journal-title":"J. Biomol. Screen."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1021\/acs.chemrev.5b00631","article-title":"Emerging Computational Methods for the Rational Discovery of Allosteric Drugs","volume":"116","author":"Wagner","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1021\/jm301557k","article-title":"Pharmacological chaperones as therapeutics for lysosomal storage diseases","volume":"56","author":"Boyd","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/adt.2011.0370","article-title":"Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders","volume":"9","author":"Valenzano","year":"2011","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1039\/C7SC04712F","article-title":"Tuning protein folding in lysosomal storage diseases: The chemistry behind pharmacological chaperones","volume":"9","author":"Pereira","year":"2018","journal-title":"Chem. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9297","DOI":"10.1039\/C7OB02281F","article-title":"In silico analyses of essential interactions of iminosugars with the Hex A active site and evaluation of their pharmacological chaperone effects for Tay-Sachs disease","volume":"15","author":"Kato","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1039\/C1MD00200G","article-title":"Non-iminosugar glucocerebrosidase small molecule chaperones","volume":"3","author":"Marugan","year":"2012","journal-title":"MedChemComm"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0705637104","article-title":"Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease","volume":"104","author":"Zheng","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ymgme.2014.05.009","article-title":"Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients","volume":"112","author":"Berardi","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1021\/ja8049063","article-title":"High-throughput thermal scanning: A general, rapid dye-binding thermal shift screen for protein engineering","volume":"131","author":"Lavinder","year":"2009","journal-title":"J. Am. Chem. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/1087057113483559","article-title":"High-throughput screen for pharmacoperones of the vasopressin type 2 receptor","volume":"18","author":"Conn","year":"2013","journal-title":"J. Biomol. Screen."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nchembio.1508","article-title":"Pharmacological chaperones stabilize retromer to limit APP processing","volume":"10","author":"Mecozzi","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1039\/C6MB00866F","article-title":"Screening methods for identifying pharmacological chaperones","volume":"13","author":"Shin","year":"2017","journal-title":"Mol. Biosyst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13052-018-0564-z","article-title":"New treatments for the mucopolysaccharidoses: From pathophysiology to therapy","volume":"44","author":"Fecarotta","year":"2018","journal-title":"Ital. J. Pediatrics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1038\/537S145a","article-title":"Lysosomal storage disorders","volume":"537","author":"Grayson","year":"2016","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: Lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40259-019-00344-7","article-title":"Vestronidase Alfa: A Review in Mucopolysaccharidosis VII","volume":"33","author":"McCafferty","year":"2019","journal-title":"BioDrugs"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","article-title":"Cerliponase Alfa: First Global Approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2018.04.003","article-title":"Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis","volume":"124","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.gene.2015.09.062","article-title":"Large scale analysis of the mutational landscape in \u03b2-glucuronidase: A major player of mucopolysaccharidosis type VII","volume":"576","author":"Khan","year":"2016","journal-title":"Gene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.expneurol.2017.09.010","article-title":"Insights into the structural biology of Gaucher disease","volume":"298","author":"Smith","year":"2017","journal-title":"Exp. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ugrinov, K.G., Freed, S.D., Thomas, C.L., and Lee, S.W. (2015). A Multiparametric Computational Algorithm for Comprehensive Assessment of Genetic Mutations in Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome). PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121511"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/humu.1189","article-title":"Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications","volume":"18","author":"Yogalingam","year":"2001","journal-title":"Hum. Mutat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ana.25069","article-title":"Prediction of phenotypic severity in mucopolysaccharidosis type IIIA","volume":"82","author":"Knottnerus","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2017.07.005","article-title":"Processing of mutant N-acetyl-\u03b1-glucosaminidase in mucopolysaccharidosis type IIIB fibroblasts cultured at low temperature","volume":"122","author":"Meijer","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lukas, J., Giese, A.-K., Markoff, A., Grittner, U., Kolodny, E., Mascher, H., Lackner, K.J., Meyer, W., Wree, P., and Saviouk, V. (2013). Functional Characterisation of Alpha-Galactosidase A Mutations as a Basis for a New Classification System in Fabry Disease. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003632"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00210592","article-title":"Intracellular processing and maturation of mutant gene products in hereditary \u03b2-galactosidase deficiency (\u03b2-galactosidosis)","volume":"93","author":"Oshima","year":"1994","journal-title":"Hum. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/BJ20070479","article-title":"Mutant \u03b1-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin","volume":"406","author":"Ishii","year":"2007","journal-title":"Biochem. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.chembiol.2011.10.012","article-title":"The Molecular Basis of Pharmacological Chaperoning in Human \u03b1-Galactosidase","volume":"18","author":"Guce","year":"2011","journal-title":"Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/humu.20828","article-title":"Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly Syndrome)","volume":"30","author":"Tomatsu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1007\/s11033-014-3383-3","article-title":"Computational analysis of human N-acetylgalactosamine-6-sulfate sulfatase enzyme: An update in genotype\u2013phenotype correlation for Morquio A","volume":"41","author":"Barrera","year":"2014","journal-title":"Mol. Biol. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4155\/fmc.14.40","article-title":"Pharmacological chaperone therapy for lysosomal storage diseases","volume":"6","author":"Parenti","year":"2014","journal-title":"Future Med. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: Preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/164_2017_68","article-title":"Pharmacological chaperones: Beyond conformational disorders","volume":"245","author":"Leidenheimer","year":"2018","journal-title":"Handb. Exp. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17400","DOI":"10.1073\/pnas.1203924109","article-title":"Pharmacological chaperones for human \u03b1-N-acetylgalactosaminidase","volume":"109","author":"Clark","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_58","first-page":"100476","article-title":"Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease","volume":"20","author":"Charkhand","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"240ra73","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A New Glucocerebrosidase Chaperone Reduces \u03b1-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteom."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1039\/C5SC00754B","article-title":"Azasugar inhibitors as pharmacological chaperones for Krabbe disease","volume":"6","author":"Hill","year":"2015","journal-title":"Chem. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/jnr.23762","article-title":"New therapeutic approaches for Krabbe disease: The potential of pharmacological chaperones","volume":"94","author":"Spratley","year":"2016","journal-title":"J. Neurosci. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/jhg.2015.61","article-title":"Chaperone therapy for Krabbe disease: Potential for late-onset GALC mutations","volume":"60","author":"Hossain","year":"2015","journal-title":"J. Hum. Genet."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1523\/JNEUROSCI.6383-09.2010","article-title":"Molecular characterization of mutations that cause globoid cell leukodystrophy and pharmacological rescue using small molecule chemical chaperones","volume":"30","author":"Lee","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological Enhancement of \u03b1-Glucosidase by the Allosteric Chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mohamed, F.E., Al-Gazali, L., Al-Jasmi, F., and Ali, B.R. (2017). Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00448"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.braindev.2015.07.006","article-title":"Chemical chaperone treatment for galactosialidosis: Effect of NOEV on \u03b2-galactosidase activities in fibroblasts","volume":"38","author":"Hossain","year":"2016","journal-title":"Brain Dev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label Phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"37583","DOI":"10.1038\/srep37583","article-title":"Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria","volume":"6","author":"Banning","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1021\/acs.jmedchem.9b00153","article-title":"Pharmacological Chaperones for the Treatment of \u03b1-Mannosidosis","volume":"62","author":"Matsumoto","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Clarke, L., Ellaway, C., Foster, H.E., Giugliani, R., Goizet, C., Goring, S., Hawley, S., Jurecki, E., Khan, Z., and Lampe, C. (2018). Understanding the Early Presentation of Mucopolysaccharidoses Disorders: Results of a Systematic Literature Review and Physician Survey. J. Inborn Errors Metab. Screen., 6.","DOI":"10.1177\/2326409818800346"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","article-title":"Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments","volume":"79","author":"Sawamoto","year":"2019","journal-title":"Drugs"},{"key":"ref_78","first-page":"165","article-title":"Mucopolysaccharidosis Type II: Clinical Features, Biochemistry, Diagnosis, Genetics, and Treatment","volume":"Volume I","author":"Tomatsu","year":"2018","journal-title":"Mucopolysaccharidoses Update (2 Volume Set)"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2017.12.428","article-title":"Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II","volume":"123","author":"Hoshina","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"15786","DOI":"10.1038\/ncomms15786","article-title":"Insights into Hunter syndrome from the structure of iduronate-2-sulfatase","volume":"8","author":"Demydchuk","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_81","first-page":"235","article-title":"Mucopolysaccharidosis Type IVA: Clinical Features, Biochemistry, Diagnosis, Genetics, and Treatment","volume":"Volume I","author":"Tomatsu","year":"2018","journal-title":"Mucopolysaccharidoses Update (2 Volume Set)"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","article-title":"Mucopolysaccharidosis IVA and glycosaminoglycans","volume":"120","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (Morquio A disease): Clinical review and current treatment","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Taylor, M., Khan, S., Stapleton, M., Wang, J., Chen, J., Wynn, R., Yabe, H., Chinen, Y., Boelens, J.J., and Mason, R.W. (2019). Hematopoietic stem cell transplantation for mucopolysaccharidoses: Past, present, and future. Biol. Blood Marrow Transplant.","DOI":"10.1016\/j.bbmt.2019.02.012"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): A phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","article-title":"Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial","volume":"114","author":"Hendriksz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/21678707.2015.1086640","article-title":"Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): Effect and limitations","volume":"3","author":"Tomatsu","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","article-title":"Effect of enzyme replacement therapy on the growth of patients with Morquio A","volume":"64","author":"Doherty","year":"2019","journal-title":"J. Hum. Genet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","article-title":"Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: Results from MOR-004, a phase III trial","volume":"37","author":"Schweighardt","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_90","first-page":"31","article-title":"Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA","volume":"1","author":"Chinen","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2015.09.011","article-title":"Hematopoietic stem cell transplantation for Morquio A syndrome","volume":"117","author":"Yabe","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-A ten-year report from the China children transplant group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1021\/acs.jmedchem.9b00428","article-title":"Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA","volume":"62","author":"Hidalgo","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_94","first-page":"415","article-title":"Ezetimibe therapy: Mechanism of action and clinical update","volume":"8","author":"Phan","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/00003495-200363100-00005","article-title":"Pranlukast: A review of its use in the management of asthma","volume":"63","author":"Keam","year":"2003","journal-title":"Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1089\/ars.2014.5844","article-title":"Engineering of protein folding and secretion-strategies to overcome bottlenecks for efficient production of recombinant proteins","volume":"21","author":"Delic","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/fmb.12.133","article-title":"Pichia pastoris: Protein production host and model organism for biomedical research","volume":"8","author":"Gasser","year":"2013","journal-title":"Future Microbiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1074\/jbc.M605984200","article-title":"A role for protein misfolding in immunogenicity of biopharmaceuticals","volume":"282","author":"Maas","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_99","first-page":"663","article-title":"The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy","volume":"13","author":"Regier","year":"2016","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"ref_100","first-page":"273","article-title":"Mucopolysaccharidosis Type IVB: Clinical Features, Biochemistry, Diagnosis, Genetics, and Treatment","volume":"Volume I","author":"Tomatsu","year":"2018","journal-title":"Mucopolysaccharidoses Update (2 Volume Set)"},{"key":"ref_101","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (1993). GLB1-Related Disorders. GeneReviews, GeneReviews\u00ae."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpn.2008.03.004","article-title":"The potential action of galactose as a \u201cchemical chaperone\u201d: Increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient","volume":"13","author":"Caciotti","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2010.03.019","article-title":"DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts","volume":"100","author":"Fantur","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1016\/j.bmcl.2011.09.012","article-title":"A fluorescent probe for GM1 gangliosidosis related beta-galactosidase: N-( dansylamino)hexylaminocarbonylpentyl-1,5-dideoxy-1,5-imino-d-galactitol","volume":"21","author":"Frohlich","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2012.06.007","article-title":"Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy","volume":"107","author":"Rigat","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2012.263","article-title":"A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis","volume":"21","author":"Takai","year":"2013","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejmech.2016.09.095","article-title":"(5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal beta-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B","volume":"126","author":"Front","year":"2017","journal-title":"Eur. J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/1\/232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:46:29Z","timestamp":1760190389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/1\/232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,29]]},"references-count":108,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["ijms21010232"],"URL":"https:\/\/doi.org\/10.3390\/ijms21010232","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201910.0365.v1","asserted-by":"object"}]},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,29]]}}}